KRISTINA WOOD: Open Payments
NPI 1215441589 · MAGEE, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$514 in 26 payments from 10 companies in 2025. Trend: 2023 $270 · 2024 $439 · 2025 $514
Food & beverage: $514
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $164 |
| Novo Nordisk Inc | 5 | $95 |
| Lilly USA, LLC | 4 | $94 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $45 |
| ABBVIE INC. | 2 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 2 | $20 |
| Inari Medical, Inc. | 1 | $19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $13 |
Products named: AIRSUPRA, Ozempic, JARDIANCE, MOUNJARO, CAPLYTA, VRAYLAR, GEMTESA, VOQUEZNA.
Industry payments across MS — which companies pay providers there.
